Mitocin (Mitomycin)

Mitomycin, the active ingredient in Mitocin, is an alkylating agent presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of various solid tumours, including bladder, gastric, pancreatic and breast cancers, in adult oncology patients and is manufactured according to EU standards.

GNH USA supplies Mitocin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and timely delivery to meet patient needs.

Mitocin is used as an antineoplastic agent targeting rapidly dividing cells in several solid tumour types.

- Bladder cancer: administered intravesically after tumor resection to reduce recurrence and progression. - Gastric cancer: combined with other chemotherapeutics to improve response rates in advanced disease. - Pancreatic cancer: incorporated into multi‑drug regimens to enhance tumor control in metastatic settings. - Breast cancer: used in selected cases as part of combination chemotherapy for refractory disease.

Mitocin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring in many patients. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Hemorrhagic cystitis: bladder inflammation with bleeding, especially after intravesical use. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe bone marrow failure: aplastic anemia or pancytopenia. - Renal impairment: acute kidney injury in susceptible individuals.

Before initiating Mitocin therapy, several precautionary measures should be observed to minimize risks.

- Renal function assessment: evaluate creatinine clearance before dosing. - Hepatic function monitoring: check liver enzymes due to metabolism involvement. - Avoid concurrent radiation: combined use increases tissue toxicity. - Monitor blood counts: perform regular CBC to detect myelosuppression early. - Pregnancy contraindication: drug is category D; avoid use in pregnant patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitocin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent alkylating agents: additive bone marrow suppression. - High-dose radiation therapy: heightened risk of tissue damage. - Nephrotoxic drugs (e.g., cisplatin): increased renal toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): enhanced bleeding risk. - CYP450 inhibitors: may alter drug activation pathways. - Immunosuppressants (cyclosporine): potential for increased toxicity.